Compugen Ltd
CGEN Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$1.97
KIRA · Stoqly’s AI analyst, in plain words
- Compugen Ltd had $72.8M of revenue in fiscal 2025, up 161.1% on the year before. Over five years, revenue changed +105.2% a year on average.
- Its operating margin was 43.1%, up 96.5 pts: of every 100 in sales, about 43 is left after running the business.
- Compugen Ltd made $35.3M of net profit in fiscal 2025.
- Free cash flow was $31.3M in fiscal 2025, 43.1% of revenue.
Market cap
$185M
P/E
5.2x
Revenue
$72.8M
Net income
$35.3M
Free cash flow
$31.3M
Operating margin
43.1%
Compugen Ltd in 30 seconds · fiscal 2025
Are sales growing?
+161.1%
Yes. Sales grew 161.1% last year.
Does it make a profit?
48.6%
Yes. It keeps 48.6% of every sale as profit.
Does profit turn into cash?
43.1%
Yes. 43.1% of sales ends up as free cash.
How healthy are the accounts?
6 / 8
Mixed. It passes 6 of 8 health tests.
How is the share priced?
5.2x
One share costs 5.2 times its yearly profit per share.
What Compugen Ltd does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 2, 2026
- Legal name
- COMPUGEN LTD
- CIK
- 0001119774
Compugen Ltd · CGEN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $6.0M | $7.5M | $33.5M | $27.9M | $72.8M |
| Revenue growth | 200.0% | 25.0% | 346.1% | −16.7% | 161.1% |
| Gross margin | 88.7% | 87.0% | 94.0% | 71.5% | 87.3% |
| Operating margin | −584.6% | −471.7% | −38.8% | −53.4% | 43.1% |
| Net income | −$34.2M | −$33.7M | −$18.8M | −$14.2M | $35.3M |
| Net margin | −570.1% | −449.3% | −56.1% | −51.1% | 48.6% |
| Diluted EPS | −$0.41 | −$0.39 | −$0.21 | −$0.16 | $0.38 |
| Cash | |||||
| Cash from operations | −$22.7M | −$34.1M | −$35.9M | $49.6M | $31.6M |
| Capital expenditure | $0.3M | $0.5M | $0.2M | $0.1M | $0.3M |
| Free cash flow | −$23.0M | −$34.6M | −$36.1M | $49.5M | $31.3M |
| FCF margin | −383.1% | −461.2% | −107.8% | 177.6% | 43.1% |
| Share count change | 5.8% | 2.8% | 1.2% | 2.2% | 4.8% |
| Debt and strength | |||||
| Cash and short-term investments | $7.8M | $11.1M | $25.6M | $41.9M | $99.9M |
| Shareholders' equity | $107M | $77.7M | $65.6M | $54.9M | $103M |
| Current ratio | 7.2x | 7.2x | 4.4x | 5.3x | 6.6x |
| Returns and quality | |||||
| Return on equity | −30.2% | −36.5% | −26.2% | −23.6% | 44.8% |
| Return on tangible equity | −32.1% | −43.4% | −28.6% | −25.9% | 34.4% |
| Piotroski F-score | 2 | 2 | 3 | 4 | 6 |
| Altman Z'' | −2.5 | −8.2 | −7.5 | −8.9 | −0.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.1M
2 insiders
Of sales under plans
100%
$0.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Compugen Ltd · CGEN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.97 a share, the company is worth $185M: 5.2 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001119774). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.